NX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 Study
RBGPF
-13.5000
The Fort Worth Press - NX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 Study
USD
-
AED 3.67315
AFN 64.99994
ALL 83.124973
AMD 376.619921
ANG 1.790083
AOA 916.999697
ARS 1386.059901
AUD 1.445965
AWG 1.8
AZN 1.660081
BAM 1.695072
BBD 2.009612
BDT 122.428639
BGN 1.709309
BHD 0.37719
BIF 2971
BMD 1
BND 1.2851
BOB 6.894519
BRL 5.141503
BSD 0.997742
BTN 92.939509
BWP 13.688562
BYN 2.956504
BYR 19600
BZD 2.006665
CAD 1.391415
CDF 2299.999874
CHF 0.798098
CLF 0.023199
CLP 916.020059
CNY 6.882597
CNH 6.875665
COP 3684.13
CRC 464.279833
CUC 1
CUP 26.5
CVE 95.875021
CZK 21.239898
DJF 177.719784
DKK 6.474045
DOP 60.625035
DZD 132.91548
EGP 54.2267
ERN 15
ETB 156.696767
EUR 0.86646
FJD 2.261499
FKP 0.75717
GBP 0.755415
GEL 2.679742
GGP 0.75717
GHS 11.010031
GIP 0.75717
GMD 73.496194
GNF 8777.501759
GTQ 7.632939
GYD 208.828972
HKD 7.83795
HNL 26.610307
HRK 6.527104
HTG 130.952897
HUF 330.965997
IDR 17028.3
ILS 3.14681
IMP 0.75717
INR 92.963598
IQD 1310
IRR 1315799.999722
ISK 125.109945
JEP 0.75717
JMD 157.303566
JOD 0.709023
JPY 159.732988
KES 130.098681
KGS 87.449851
KHR 4012.474966
KMF 427.000011
KPW 899.999766
KRW 1508.840244
KWD 0.30934
KYD 0.831502
KZT 472.805432
LAK 21959.999545
LBP 89550.000317
LKR 314.804623
LRD 184.249994
LSL 16.864992
LTL 2.95274
LVL 0.60489
LYD 6.375004
MAD 9.377501
MDL 17.55613
MGA 4160.999683
MKD 53.34747
MMK 2099.768269
MNT 3572.241801
MOP 8.055104
MRU 40.120228
MUR 47.000425
MVR 15.449863
MWK 1736.498722
MXN 17.779002
MYR 4.027503
MZN 63.959822
NAD 16.869726
NGN 1379.170054
NIO 36.730165
NOK 9.72108
NPR 148.701282
NZD 1.75009
OMR 0.384111
PAB 0.997734
PEN 3.42625
PGK 4.307027
PHP 60.104502
PKR 279.050152
PLN 3.705502
PYG 6454.29687
QAR 3.645097
RON 4.417601
RSD 101.640096
RUB 80.179597
RWF 1461
SAR 3.7548
SBD 8.04524
SCR 14.423971
SDG 600.999946
SEK 9.436305
SGD 1.28509
SHP 0.750259
SLE 24.598585
SLL 20969.510825
SOS 571.505074
SRD 37.351059
STD 20697.981008
STN 21.55
SVC 8.730169
SYP 110.564494
SZL 16.860389
THB 32.579566
TJS 9.563492
TMT 3.5
TND 2.918991
TOP 2.40776
TRY 44.592298
TTD 6.768937
TWD 31.955502
TZS 2600.000122
UAH 43.698134
UGX 3743.234401
UYU 40.405091
UZS 12174.999793
VES 473.4672
VND 26336.5
VUV 119.305544
WST 2.766278
XAF 568.506489
XAG 0.013737
XAU 0.000215
XCD 2.70255
XCG 1.798209
XDR 0.706253
XOF 568.523004
XPF 103.650115
YER 238.59594
ZAR 16.83949
ZMK 9001.19364
ZMW 19.281421
ZWL 321.999592
- Tiger's treatment battle in thoughts of stars at Masters
- Thai amateur 'Fifa' ready for Masters kick-off
- 'Hacks' has 'perfect' ending after 5 seasons, says star Smart
- Age and near misses don't worry Rose in Masters quest
- 'Incredibly dangerous': rescuing downed fighter crew in Iran
- Wall Street stocks rise on hopes for US-Iran ceasefire
- Artemis astronauts breaks space distance record
- High-flying Villarreal stumble at Girona
- Promoter defends plan for Kanye West to headline London fest
- Napoli's Serie A title defence boosted by beating AC Milan
NX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 Study
LEXINGTON, KY / ACCESS Newswire / April 6, 2026 / NX Development Corp (NXDC) is pleased to announce that after successfully completing the data analysis of our MEN-301 Study of the use of Gleolan® (aminolevulinic acid HCl) to enhance visualization of newly diagnosed or recurrent meningioma, we have submitted these data to the FDA for review as part of an efficacy supplement to our Gleolan New Drug Application (NDA).
"This marks the first submission of supplemental data to the FDA since our original approval for high-grade glioma in 2017, and the culmination of a great amount of hard work by our dedicated NXDC team in advancing the science of fluorescence-guided surgery," said Salvatore DeSena, MD, CEO of NX Development Corp. "Without doubt we are pleased with these results, and we look forward to the FDA review process."
"This submission to the FDA is another important milestone not only for NXDC but also for our whole group," added Dr. Ulrich Kosciessa, Chairman of the Board of NXDC and CEO of photonamic GmbH & Co. KG. "We are dedicating our full attention to provide solutions for unmet medical needs using 5-Aminolevulinic Acid (5-ALA) in the field of fluorescence-guided surgery for patients and healthcare professionals globally."
About NX Development Corp. (NXDC)
NXDC is a privately held life science company dedicated to the commercialization of Gleolan in the U.S. The company was acquired in 2018 by photonamic (PHN) GmbH & Co. KG. (Pinneberg, Germany). PHN is wholly owned by SBI ALApharma GmbH (Germany), a subsidiary of SBI Holdings, Inc. (Tokyo, Japan).
About Gleolan® (aminolevulinic acid HCl)
Gleolan is an FDA-approved optical imaging agent indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. Gleolan helps neurosurgeons see malignant tissue in real time during surgery and is provided orally (20mg/kg), 2-4 hours prior to glioma surgery. During the operation, the surgeon utilizes a surgical microscope with a specific blue light filter for the visualization of red-violet fluorescence.
Please see Full Prescribing Information.
Contact: Phone: 833-471-3282 | Email: [email protected]
SOURCE: NX Development Corp
View the original press release on ACCESS Newswire
D.Johnson--TFWP
